Children
(Mar 2022)
Safety of Monoclonal Antibodies in Children Affected by SARS-CoV-2 Infection
Lorenza Romani,
Francesca Ippolita Calò Carducci,
Sara Chiurchiù,
Laura Cursi,
Maia De Luca,
Martina Di Giuseppe,
Andrzej Krzysztofiak,
Laura Lancella,
Paolo Palma,
Leonardo Vallesi,
Tiziana Corsetti,
Andrea Campana,
Emanuele Nicastri,
Paolo Rossi,
Stefania Bernardi
Affiliations
Lorenza Romani
Immunology and Infectious Disease Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Francesca Ippolita Calò Carducci
Immunology and Infectious Disease Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Sara Chiurchiù
Immunology and Infectious Disease Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Laura Cursi
Immunology and Infectious Disease Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Maia De Luca
Immunology and Infectious Disease Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Martina Di Giuseppe
Immunology and Infectious Disease Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Andrzej Krzysztofiak
Immunology and Infectious Disease Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Laura Lancella
Immunology and Infectious Disease Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Paolo Palma
Research Unit of Congenital and Perinatal Infections, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Leonardo Vallesi
Hospital Pharmacy Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Tiziana Corsetti
Hospital Pharmacy Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Andrea Campana
Department of Pediatrics, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
Emanuele Nicastri
National Institute for Infectious Diseases, Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
Paolo Rossi
Chair of Pediatrics, Department of Systems Medicine, University of Rome “Tor Vergata”, 00133 Rome, Italy
Stefania Bernardi
Immunology and Infectious Disease Unit, Bambino Gesù Children’s Hospital, IRCCS, 00165 Rome, Italy
DOI
https://doi.org/10.3390/children9030369
Journal volume & issue
Vol. 9,
no. 3
Abstract
Read online
Monoclonal antibody therapies for COVID-19 have been frequently used in adults, whereas there are little data regarding the safety or efficacy of monoclonal antibody treatments in pediatric patients affected by COVID-19. We report our experience in the administration of mAb as a treatment for SARS-CoV-2 infection in children aged from 24 days to 18 years old.
Keywords
WeChat QR code
Close
